Major R&D Pipeline: 3ADCs

DS-3201 (EZH1/2 inhibitor): Presented interim results of NHL Ph1 study at EHA DS3201-A-J101; NCT02732275 Patients with R/R NHL Age ≥20 (Japan) or ≥18 (US) years ECOG PS 0 or 1 Patients with ATL: positive test result for HTLV-1 Primary endpoints . . · Safety (including DLTS, TEAEs) Recommended phase 2 dose Pharmacokinetics Secondary endpoints Part 1: Dose Escalation Japan R/R NHL (all-comers) b 300 mg PO, QD RDE 250 mg PO, QD 200 mg PO, QD 150 mg PO, QD Part 2: Dose Expansion Japan and US R/R ATL Valemetostat 200 mg PO, QD R/R PTCL Valemetostat 200 mg PO, QD • Safety analysis: all NHL (N=77) • Safety and efficacy analyses: T-cell NHL (n=58) · Safety • Antitumor effecta o PTCL (n=44) o ATL (n=14) a According to the 2007 revised International Working Group Criteria for Malignant Lymphoma or "Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting." b Each dosage was tested with 3 patients. ATL: adult T-cell leukemia/lymphoma, EHA: European Hematology Association, NHL: non Hodgkin's lymphoma, PTCL: peripheral T-cell lymphoma, R/R: relapsed/refractory Daiichi-Sankyo 23

View entire presentation